Last reviewed · How we verify
NCT02833259: R3P
Avoidable Readmissions For Patients Hospitalized With Community-Acquired Pneumonia
trial in Community-acquired Pneumonia in 1,150 participants. Completed in 1 January 2022.
1 September 2021
Quick facts
| Lead sponsor | University Hospital, Grenoble |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 1,150 |
| Start date | 10 May 2017 |
| Primary completion | 1 September 2021 |
| Estimated completion | 1 January 2022 |
| Sites | 2 locations across France |
Conditions studied
- Community-acquired Pneumonia — all drugs for Community-acquired Pneumonia →
Sponsor
University Hospital, Grenoble
Who can join
18 and older, any sex, with Community-acquired Pneumonia. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
From 10% to 30% of patients hospitalized with community-acquired pneumonia (CAP) are readmitted within 30 days of discharge. These readmissions have negative consequences for the patients and the hospitals where they are treated, including impaired quality of life, exposure to hospital-related adverse events, and increased resource utilization. Risk-adjusted readmission rates can be easily computed and tracked from computerized hospital discharge data, using validated models. As part of the Hospital Readmission Reduction Program (HRRP) effective in fiscal year 2013, United States hospitals with higher than expected 30-day readmission rates after pneumonia hospitalization have been subject to financial penalties from the Center for Medicare and Medicaid Services (CMS). The underlying logic of the HRRP is based upon the notion that short-term readmission is often a preventable adverse outcome, reflecting suboptimal quality of care during index hospitalization. Yet, published evidence suggests that less than one in four all-cause readmissions are deemed avoidable. Because only avoidable readmissions can be influenced by interventions designed to decrease readmission rates, avoidable readmission is a more relevant metric than all-cause readmission for tracking quality of hospital care for pneumonia. The purpose of this study is to develop an administrative data-based risk prediction model for identifying potentially avoidable readmissions within 30 days of discharge for patients hospitalized with CAP. R3P is a retrospective observational cohort study of consecutive adult patients discharged from two hospitals with a diagnosis code of CAP. Data sources include routinely collected hospital discharge data and retrospective chart reviews.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Development of a risk prediction model of potentially avoidable readmission for patients hospitalised with community-acquired pneumonia: study protocol and population.
Mounayar AL, Francois P, Pavese P, Sellier E, et al · · 2020 · cited 8× · PMID 33177142 · DOI 10.1136/bmjopen-2020-040573
Verify or expand the search:
- PubMed search for NCT02833259
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Community-acquired Pneumonia
Currently open trials in the same condition.
- NCT07164131 — Azithromycin Versus Doxycycline in Hospitalized Adult Patients With Community Acquired Pneumonia Treated With Beta-lacta · Phase 4 · recruiting
- NCT06577558 — Efficacy and Safety of SR1375 in Adult Patients With CAP · Phase 2 · recruiting
- NCT06229288 — Amoxicillin Alone Versus Amoxicillin/Clavulanate for Community-acquired Pneumonia in Patients Aged 65 Years or Older, an · Phase 3 · recruiting
- NCT06125340 — Optimizing Care for Children Hospitalized With Community-acquired Pneumonia: Short-course Therapy · Phase 4 · recruiting
- NCT06114888 — Optimizing Care for Children Hospitalized With Community-acquired Pneumonia: Novel Diagnostics · NA · recruiting
Other University Hospital, Grenoble trials
Trials by the same sponsor.
- NCT07479225 — Circulating Cell-Free DNA for Brain Abscess Diagnosis: A Pilot Study · NA · not yet recruiting
- NCT07477613 — Implantable Brain-Computer Interface for Upper-Limb Recovery After Stroke · NA · not yet recruiting
- NCT07379372 — Bladder Overactivity and Post-Botulinum Toxin Telemonitoring · NA · not yet recruiting
- NCT07166991 — Anesthesia sTrategy foR Organ Procurement In braiN dEath · Phase 3 · recruiting
- NCT07367880 — The Monument Test : A New Tool for Assessing the Ability to Name and Identify Unique Entities. (TeDIMO) · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT02833259 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University Hospital, Grenoble
- Last refreshed: 1 June 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02833259.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing